Adjuvant effects of CpG oligodeoxynucleotides on responses against T‐independent type 2 antigens

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Immunology

• Publication date

  2001-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1046/j.1365-2567.2001.01158.xPMID 11168639PMCID PMC1783157
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CD4 and CD8 Expression by Dendritic Cell Subtypes in Mouse Thymus and Spleen1

  2000cited by this paper
• CpG Oligodeoxynucleotides Act as Adjuvants for Pneumococcal Polysaccharide-Protein Conjugate Vaccines and Enhance Antipolysaccharide Immunoglobulin G2a (IgG2a) and IgG3 Antibodies

  2000cited by this paper
• Synthetic oligodeoxynucleotide containing CpG motif induces an anti-polysaccharide type 1-like immune response after immunization of mice with Haemophilus influenzae type b conjugate vaccine.

  2000cited by this paper
• CpG oligodeoxynucleotides overcome the unresponsiveness of neonatal B cells to stimulation with the thymus‐independent stimuli anti‐IgM and TNP‐Ficoll

  1999cited by this paper
• Bacterial CpG DNA activates immune cells to signal infectious danger.

  1999cited by this paper
• CpG oligodeoxynucleotides rescue BKS-2 immature B cell lymphoma from anti-IgM-mediated growth inhibition by up-regulation of egr-1.

  1999cited by this paper
• CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming.

  1999cited by this paper
• Enhancement of T cell-independent immune responses in vivo by CD40 antibodies

  1998cited by this paper
• IL-12 enhances antibody responses to T-independent polysaccharide vaccines in the absence of T and NK cells.

  1998cited by this paper
• CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.

  1998cited by this paper
• Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor.

  1998cited by this paper
• Characterization of Early Activation Events in Cord Blood B Cells after Stimulation with T Cell-Independent Activators

  1998cited by this paper
• Neonatal murine B lymphocytes respond to polysaccharide antigens in the presence of IL-1 and IL-6.

  1998cited by this paper
• CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species.

  1998cited by this paper
• CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice.

  1998cited by this paper
• CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge.

  1998cited by this paper
• Mitogenic synthetic polynucleotides suppress the antibody response to a bacterial polysaccharide.

  1998cited by this paper
• The consequences of the intracellular retention of pathogen-derived T-cell-independent antigens on protein presentation to T cells.

  1997cited by this paper
• Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants

  1997cited by this paper
• CpG Oligodeoxynucleotides Act as Adjuvants that Switch on T Helper 1 (Th1) Immunity

  1997cited by this paper
• Restoration of T cell-independent type 2 induction of Ig secretion by neonatal B cells in vitro.

  1997cited by this paper
• CpG‐containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: A new class of vaccine adjuvants

  1997cited by this paper
• Inhibitory effects of thymus-independent type 2 antigens on MHC class II-restricted antigen presentation: comparative analysis of carbohydrate structures and the antigen presenting cell.

  1997cited by this paper
• Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization.

  1997cited by this paper
• Neonatal and early life immune responses to various forms of vaccine antigens qualitatively differ from adult responses: predominance of a Th2‐biased pattern which persists after adult boosting

  1996cited by this paper
• T cell-independent antigens type 2.

  1995cited by this paper
• CpG motifs in bacterial DNA trigger direct B-cell activation

  1995cited by this paper
• Antibody Response to Pneumococcal Polysaccharide Vaccine in Young, Adult and Old Mice

  1993cited by this paper
• In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. I. In vivo expression of CD40 ligand, cytokines, and antibody production delineates sites of cognate T-B cell interactions

  1993cited by this paper
• Marginal zone macrophages and their role in the immune response against T‐independent type 2 antigens: modulation of the cells with specific antibody

  1989cited by this paper
• Differential responses of B cells from the spleen and lymph node to TNP-Ficoll.

  1988cited by this paper
• Splenic dependence of the antibody response to thymus‐independent (TI‐2) antigens

  1985cited by this paper
• T cell regulation of IgG subclass antibody production in response to T- independent antigens

  1981cited by this paper
• Role of accessory cells in B cell activation. I. Macrophage presentation of TNP-Ficoll: evidence for macrophage-B cell interaction.

  1980cited by this paper
• Role of a nonimmunoglobulin cell surface determinant in the activation of B lymphocytes by thymus-independent antigens

  1979cited by this paper
• The ontogeny of thymic independent antibody responses in vitro in normal mice and mice with an X-linked B cell defect.

  1977cited by this paper
• Characterization of the antibody response to type 3 pneumococcal polysaccharide at the cellular level. I. Dose-response studies and the effect of prior immunization on the magnitude of the antibody response.

  1971cited by this paper
• STUDIES ON THE INDUCTION OF IMMUNOLOGICAL UNRESPONSIVENESS TO PNEUMOCOCCAL POLYSACCHARIDE IN MICE

  1966cited by this paper

• Optimizing Humoral Immunity for Durable and Broad Protection in Flavivirus Vaccines

  2025cites this paper
• Environmental signals rather than layered ontogeny imprint the function of type 2 conventional dendritic cells in young and adult mice

  2021cites this paper
• Environmental signals rather than layered ontogeny imprint the function of type 2 conventional dendritic cells in young and adult mice

  2021cites this paper
• Adjuvanted leptospiral vaccines: Challenges and future development of new leptospirosis vaccines.

  2019cites this paper
• Immunogenic Responses of Effective Vaccine Candidates against Streptococcus agalactiae in Ruminants

  2019cites this paper
• Evaluation of the Immunomodulatory Properties of Streptococcus suis and Group B Streptococcus Capsular Polysaccharides on the Humoral Response

  2017cites this paper
• The Humoral Immune Response to T Cell–Independent Antigens

  2016cites this paper
• Protection against Streptococcus suis Serotype 2 Infection Using a Capsular Polysaccharide Glycoconjugate Vaccine

  2016influential citation
• Differential regulation of polysaccharide-specific antibody responses to isolated polysaccharides, conjugate vaccines, and intact Gram-positive versus Gram-negative extracellular bacteria.

  2016cites this paper
• Development of chitosan–pullulan composite nanoparticles for nasal delivery of vaccines: in vivo studies

  2015cites this paper
• PD-1 Suppresses Protective Immunity to Streptococcus pneumoniae through a B Cell–Intrinsic Mechanism

  2015cites this paper
• This information is current as Intrinsic Mechanism − through a B Cell Streptococcus pneumoniae PD-1 Suppresses Protective Immunity to

  2015cites this paper
• Bacterial polysaccharide-mediated downregulation of TACI and B-cell apoptosis contribute to the hyporesponsiveness against bacterial polysaccharides vaccines.

  2013cites this paper
• Nasopharyngeal Colonization in Mice Cellular Immune Responses as Well as Vaccination Impacts Both Humoral and Administration in Pneumococcal Timing of Toll-Like Receptor 9 Agonist

  2012cites this paper
• Timing of Toll-Like Receptor 9 Agonist Administration in Pneumococcal Vaccination Impacts Both Humoral and Cellular Immune Responses as Well as Nasopharyngeal Colonization in Mice

  2012cites this paper
• Suppressive Effect of Bacterial Polysaccharides on BAFF System Is Responsible for Their Poor Immunogenicity

  2011cites this paper
• Mode of Adjuvant Action of the Nasally Delivered Cytokine Interleukin 1 Alpha

  2011cites this paper
• This information is current as Responsible for Their Poor Immunogenicity Polysaccharides on BAFF System Is Suppressive Effect of Bacterial Uslu

  2011cites this paper
• This information is current as Responsible for Their Poor Immunogenicity Polysaccharides on BAFF System Is Suppressive Effect of Bacterial Uslu

  2011cites this paper
• This information is current as Responsible for Their Poor Immunogenicity Polysaccharides on BAFF System Is Suppressive Effect of Bacterial Uslu

  2011cites this paper
• Toll-like receptor agonists allow generation of long-lasting antipneumococcal humoral immunity in response to a plain polysaccharidic vaccine.

  2010cites this paper
• Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial.

  2010cites this paper
• The contribution of naturally occurring IgM antibodies, IgM cross-reactivity and complement dependency in murine humoral responses to pneumococcal capsular polysaccharides.

  2009cites this paper
• The thymus-independent immunity conferred by a pneumococcal polysaccharide is mediated by long-lived plasma cells.

  2009cites this paper
• B-cell responses to vaccination at the extremes of age

  2009cites this paper
• Chapter 10 – What Insights Into Human Cord Blood Lymphocyte Function Can Be Gleaned From Studying Newborn Mice?

  2008cites this paper
• Adult-Like Anti-Mycobacterial T Cell and In Vivo Dendritic Cell Responses Following Neonatal Immunization with Ag85B-ESAT-6 in the IC31® Adjuvant

  2008cites this paper
• Effects of LT‐K63 and CpG2006 on Phenotype and Function of Murine Neonatal Lymphoid Cells

  2007cites this paper
• CpG oligodeoxynucleotides induce cyclooxygenase-2 in human B lymphocytes: implications for adjuvant activity and antibody production.

  2007cites this paper
• Photodynamic therapy‐generated tumor cell lysates with CpG‐oligodeoxynucleotide enhance immunotherapy efficacy in human papillomavirus 16 (E6/E7) immortalized tumor cells

  2007cites this paper
• Synthetic CpG oligodeoxynucleotides augment BAFF‐ and APRIL‐mediated immunoglobulin secretion

  2007cites this paper
• CpG ODN As a Th1 Immune Enhancer for Prophylactic and Therapeutic Vaccines

  2006cites this paper
• Immunomodulatory properties of meningococcal outer membrane vesicles.

  2006cites this paper
• Immunization of Aged Mice with a Pneumococcal Conjugate Vaccine Combined with an Unmethylated CpG-Containing Oligodeoxynucleotide Restores Defective Immunoglobulin G Antipolysaccharide Responses and Specific CD4+-T-Cell Priming to Young Adult Levels

  2006cites this paper
• Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA.

  2006cites this paper
• The role of B cells and accessory cells in the neonatal response to TI-2 antigens

  2005influential citation
• Chapter 53 – CpG Oligodeoxynucleotides for Mucosal Vaccines

  2005cites this paper
• Agonists of Toll-Like Receptor 9

  2005cites this paper
• Immune responses to and adjuvant properties of bacterial capsular polysaccharides.

  2004cites this paper
• Neonatal immunity to polysaccharide antigens: role of B cells versus macrophages

  2004cites this paper
• Host defense against pulmonary infection in neonates

  2004cites this paper
• Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response.

  2004cites this paper
• Dendritic cell maturation and antigen presentation.

  2004cites this paper
• CpG DNA: Trigger of Sepsis, Mediator of Protection, or Both?

  2003cites this paper
• CpG-motifs enhance initial and sustained primary tetanus-specific antibody secreting cell responses in spleen and bone marrow, but are more effective in adult than in neonatal mice.

  2003cites this paper
• The Use of DNA Vaccines for Neonatal/Early Life Childhood Immunization

  2003cites this paper
• DNA Immunization with Hepatitis C Virus (HCV) Polycistronic Genes or Immunization by HCV DNA Priming-Recombinant Canarypox Virus Boosting Induces Immune Responses and Protection from Recombinant HCV-Vaccinia Virus Infection in HLA-A2.1-Transgenic Mice

  2003cites this paper
• Medicinal chemistry and therapeutic potential of CpG DNA.

  2002cites this paper
• in HLA-A 2 . 1-Transgenic Mice Recombinant HCV-Vaccinia Virus Infection Responses and Protection from Canarypox Virus Boosting Induces Immune by HCV DNA Priming-Recombinant Immunization ( HCV ) Polycistronic Genes or DNA Immunization with Hepatitis C Virus

  2002cites this paper
• Lyophilization and the Thermostability of Vaccines

  2002cites this paper
• Design, synthesis, and immunostimulatory properties of CpG DNAs containing alkyl-linker substitutions: role of nucleosides in the flanking sequences.

  2002cites this paper